Counterfeit-Resistant Prescription Blanks

DEPARTMENT OF HEALTH
Division of Medical Quality Assurance

Rule No. : RULE TITLE :
64B-7.003: Counterfeit-Resistant Prescription Blanks

NOTICE OF CORRECTION

Notice is hereby given that the following correction has been made to the proposed rule in Vol. 36 No. 45, November 12, 2010 issue of the Florida Administrative Weekly.

The FSU Center for Economic Forecasting and Analysis (Center) prepared an economic analysis and revised the SERC in compliance with Chapter 2010-279, Laws of Florida. JAPC suggested corrections and, on February 14, 2011, the Center issued the revised SERC.

The SERC economic analysis shows that the proposed rule is not likely to adversely impact economic growth, job creation, investment, business competitiveness, productivity, or innovation in excess of $1 million in the aggregate within 5 years after rule implementation. The economic analysis shows that the proposed rule is likely to increase regulatory costs, including transactional costs, in excess of $1 million in the aggregate within 5 years after rule implementation and, therefore, the rule requires legislative ratification. It estimates the number of pain-management clinic physicians who are subject to the rule. The rule will not affect costs to the agency, other governmental entities, nor will it effect state or local revenues. Transactional costs of approximately 3.8 cents per controlled substance prescription yield a total of over $422,500 per year statewide, but no other transactional costs are expected. The rule affects small businesses, but is not expected to affect small counties or cities. Alternatives to the proposal were not submitted to the department.

The person to be contacted regarding the above notice is: Anthony Jusevitch, Executive Director, 4052 Bald Cypress Way, Bin C #06, Tallahassee, Florida 32399-3253.